GlycoMimetics Appoints Patricia S. Andrews to Its Board of Directors

6/12/17

Patricia S. Andrews

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ:GLYC) announced today the appointment of Patricia S. Andrews, chief executive officer and director of Boston Biomedical, Inc., to its Board of Directors.

“It’s an asset to our Board and GlycoMimetics as a whole to be able to leverage Pat’s commercial experience in oncology," said Rachel King, CEO of GlycoMimetics. "Her track record of leadership in transitioning companies to the commercial stage will be particularly helpful to us as we continue to advance our pipeline.”

Ms. Andrews was named CEO of Boston Biomedical in April 2017. She joined the company in 2013 and was most recently its Executive Vice President and Chief Operating Officer, where she prepared for launching the company’s first product, and guided the company’s pipeline development. Previously, she was Executive Vice President and Chief Commercial Officer at Incyte Corporation (NASDAQ:INCY), leading commercial operations for that company’s launch of first-in-class, first-in-disease oncology product Jakafi®. Before that, she served in leadership positions at Pfizer, Inc., where her final role was Vice President and General Manager of the U.S. Oncology Business Unit, and at Marine Midland/HSBC, where she was Vice President in corporate finance. Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. from Brown University.

"I'm honored to serve on the Board of Directors of GlycoMimetics, which has impressed me with its management team and promising pipeline of treatments targeting some of today’s most serious medical challenges in oncology," said Ms. Andrews. "I believe these clinical assets have potential in areas of high unmet need, and I look forward to helping the company rapidly progress its drug candidates towards commercialization."

Ms. Andrews was introduced to GlycoMimetics through an initiative sponsored by LifeSci Advisors for the placement of women on boards of directors in the life sciences industry. “On behalf of the GlycoMimetics management and Board, I’d like to thank LifeSci Advisors for its Board Placement Initiative, which assisted in helping to identify several outstanding director candidates, including Pat,” Ms. King added.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics’ most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial in multiple myeloma. The U.S. FDA recently granted GMI-1271 Breakthrough Therapy designation for treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.

Connect with these Baltimore Professionals on LinkedIn

  • Edwin Warfield

    Editor in Chief, Warfield Digital

    Connect
  • Jean Halle

    Independent Consultant

    Connect
  • Larry Lichtenauer

    President of Lawrence Howard & Associates

    Connect
  • Newt Fowler

    Partner at Womble Carlyle, LLP

    Connect
  • David Crowley

    Owner at Develop DC

    Connect
  • Carolyn Stinson

    Stinson Marketing Group

    Connect